UK Markets open in 3 hrs 27 mins

Compass Therapeutics, Inc. (CMPX)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
5.350.00 (0.00%)
At close: 2:15PM EDT

Compass Therapeutics, Inc.

80 Guest Street
Suite 601
Boston, MA 02135
United States
617 500 8099

Full-time employees31

Key executives

NameTitlePayExercisedYear born
Dr. Thomas J. SchuetzCo-Founder, CEO & Director4kN/A1961
Dr. Vered Bisker-Leib Ph.D., MBACOO & Pres520kN/A1971
Mr. Neil L. Lerner CPAVP of Fin.N/AN/A1968
Dr. Susan Kalled Ph.D.Chief Scientific OfficerN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Compass Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing antibody therapeutics for treating solid tumors and hematological malignancies. The company's lead product candidate is CTX-471, a monoclonal antibody agonist of CD137, a co-stimulatory receptor on immune cells that is in Phase 1b clinical trial. It also plans to initiate a second Phase 1 trial of CTX-471 in combination with trastuzumab for Her2 positive tumors, as well as with cetuximab in EGFR positive tumors. In addition, the company's product candidates include CTX-8371, a bispecific antibody that targets PD-1 and PD-L1. Further, it is developing a portfolio of bispecific and monoclonal antibody product candidates, which are in preclinical development. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Corporate governance

Compass Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.